Drug Profile
Rozanolixizumab - UCB
Alternative Names: Rozanolixizumab-noli; RYSTIGGO; UCB-7665Latest Information Update: 23 Feb 2024
Price :
$50
*
At a glance
- Originator UCB
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Neonatal Fc receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Myasthenia gravis
- Phase III CNS disorders; Idiopathic thrombocytopenic purpura
- Phase II Chronic inflammatory demyelinating polyradiculoneuropathy; Encephalitis; Fibromyalgia
Most Recent Events
- 25 Jan 2024 UCB Biopharma completes a phase III trial in Myasthenia gravis in Denmark, Hungary, Belgium, Canada, China, Czech Republic, France, Georgia, Germany, Italy, Japan, Poland, Russia, Serbia, Spain and the US (EudraCT2020-003230-20) (NCT04650854)
- 23 Jan 2024 UCB Biopharma's expanded-access programme for rozanolixizumab in Chronic inflammatory demyelinating polyradiculoneuropathy (In adults, In elderly) is no longer available (NCT05014724) .
- 08 Jan 2024 Registered for Myasthenia gravis (In adults, Adjunctive treatment) in European Union (SC)